Will my vitiligo spread?
Nobody can tell you. Not a dermatologist, not a photograph, and not this page. Vitiligo can stay much the same for years, change slowly, or change quickly. A clinician can describe what your skin has done so far. That is a different thing from a forecast. Evidence Evidence Evidence
Why this matters
Clinical guidance separates the pattern of vitiligo from how active it appears. Activity is described from your history, an examination, and change seen between visits.
Questions for your clinician
- What are you using to call my vitiligo active or stable?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would change that judgement?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does it mean when someone calls my vitiligo active or unstable?
It is a clinical judgement about how much your skin has been changing lately. It is not a score you can work out at home. It matters because apparent activity is one of the things that shapes which options a specialist will raise. Evidence Evidence
Why this matters
Consensus guidance treats apparent activity, extent, body site, age, goals, and burden as factors in the discussion. The reason an option comes up matters more than its category name.
Questions for your clinician
- Would you call my skin active right now, and how sure are you?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Does that judgement change what we would discuss?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Can a sunburn, a cut or a tattoo make new patches?
For some people it can. New patches at the site of an injury have a name: the Koebner phenomenon, also called the isomorphic response. The name is the useful part, because it is what the research is filed under. Nothing tells you in advance whether your own skin does this. If you burned skin you were treating, that is a question for the team who prescribed the treatment. Evidence Evidence Evidence
Why this matters
Consensus guidance defines it as patches that appear where previously unaffected skin was injured. The AAD names cuts, scrapes, burns and the wound a tattoo makes, and says new spots can show up about 10 to 14 days later.
Questions for your clinician
- Have you seen new patches follow an injury on my skin?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- If I get a burn or a deep scrape, what do you want me to do?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is anything meant to slow it down?
Some options are raised with the goal of settling activity rather than returning color. Consensus guidance describes selected off-label whole-body medicines for vitiligo that looks unstable or is changing quickly. That is a specialist conversation. It is not a promise that change will stop. Evidence Evidence
Why this matters
International and Canadian consensus documents both describe selected off-label systemic use in unstable or rapidly progressing disease. They treat it as a bounded specialist decision, with the health history, competing risks, and follow-up all in scope.
Questions for your clinician
- Are you trying to slow new change, support color returning, or both?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would tell us this is not doing what we hoped?Saving keeps this on your device and needs JavaScript, which is off in this browser.
How would anyone judge whether it is slowing?
By comparing what your skin does over time, not by one appointment. Keep a dated note of new patches and of changes in the ones you already had. Bring it. A clinician reads it next to the examination, not instead of it. Evidence Evidence Evidence
Why this matters
Guidance recognizes repeated standardized photographs as one way to document vitiligo over time. Structured measures such as the Vitiligo Area Scoring Index exist so that research and clinic reviews can describe extent and change more consistently.
Questions for your clinician
- What would you like me to write down before the next visit?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- When you compare these photos, what counts as a real change?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if it keeps changing anyway?
Then the plan is worth another look, and so is the goal. Slowing change, bringing color back, covering the patches, and doing none of those are separate goals. People move between them. Changing your mind is not a failure. Evidence Evidence
Why this matters
Guidelines include quality of life, side effects, day-to-day effort, and personal goals in a management review. That view separates “the photo looks the same” from “nothing important happened.”
Questions for your clinician
- Does the goal we agreed on still fit what I want?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would make you suggest a different path?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-21.
- What this evidence supports
- Clinical guidance separates the pattern of vitiligo from how active it appears. Activity is described from your history, an examination, and change seen between visits.
- What it does not establish
- Past stability does not guarantee future stability. A recent change does not reveal the whole course. Even the meaning of “stable” has limits, especially as one whole-body label.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- JAMA Dermatology (Ezzedine K, et al.)Observational study · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports defined research use and psychometric evaluation of facial and total VASI measures and the need to interpret score change in the studied context.
What it does not support
The analysis used sponsor trial data and included AbbVie authors; it does not establish one personally meaningful outcome, validate untrained home scoring or provide a treatment-change rule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Dermatology and Therapy (Prajapati VH, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Incyte funded the study, journal fee, and medical-writing support. The article says Incyte had no editorial control; authors also disclosed relevant company relationships.
What this source supports
Supports a current consensus map in which treatment choices depend on activity, extent, site, age, goals and burden, and in which selected systemic medicines may be considered off-label for unstable or rapidly progressing disease.
What it does not support
It is Canadian expert consensus with disclosed relationships, not US regulatory approval, comparative proof, a dosing guide or an individual treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations. Classification is a clinical and longitudinal judgment. Its section on the Koebner phenomenon supports defining that phenomenon as patches developing at sites of previously unaffected skin that was specifically injured. It endorses the Vitiligo European Task Force classification of that phenomenon into history-based, clinical-observation-based and experimentally induced forms. Its section on mucosal vitiligo defines that term as the oral or genital mucosae. Where the patches are at one site alone, and especially a genital one, that section says a differential diagnosis of lichen sclerosus should be addressed by biopsy. It records that genital lichen sclerosus and vitiligo have been reported together.
What it does not support
It does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response. On the Koebner phenomenon it records a general impression that the phenomenon and disease stability are related, then states that objective data are lacking. It also says scientific evidence is lacking for attributing vitiligo to daily friction from washing, dressing, personal care, sports, occupational activity or pressure from clothing. On lichen sclerosus it cites one reference from 2000 and calls a link a possibility, not a finding. It counts nothing and gives no rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DermNet (author Luo A, chief editor Oakley A)Patient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the naming only: that the Koebner phenomenon is also written Köbner phenomenon and is also called the isomorphic response, and that vitiligo is one of the conditions in which it is regularly described. It is cited here so that a reader has both search terms the literature is filed under.
What it does not support
It is a 2014 reference page written by a medical student under a dermatologist chief editor, and it is not evidence for how often this happens, for whom, or for what any particular injury will do. Nothing on it is used here for frequency, prediction or a course of action.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.